Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Change in Receivables (2016 - 2025)

United Therapeutics (UTHR) has disclosed Change in Receivables for 17 consecutive years, with $52.5 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 184.0% to $52.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.9 million through Dec 2025, up 17625.0% year-over-year, with the annual reading at $70.9 million for FY2025, 17625.0% up from the prior year.
  • Change in Receivables hit $52.5 million in Q4 2025 for United Therapeutics, up from -$81.6 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $138.1 million in Q2 2023 to a low of -$85.9 million in Q1 2023.
  • Historically, Change in Receivables has averaged $9.6 million across 5 years, with a median of $11.5 million in 2022.
  • Biggest five-year swings in Change in Receivables: tumbled 858.82% in 2021 and later soared 4832.14% in 2023.
  • Year by year, Change in Receivables stood at -$14.1 million in 2021, then rose by 19.86% to -$11.3 million in 2022, then skyrocketed by 279.65% to $20.3 million in 2023, then tumbled by 407.88% to -$62.5 million in 2024, then soared by 184.0% to $52.5 million in 2025.
  • Business Quant data shows Change in Receivables for UTHR at $52.5 million in Q4 2025, -$81.6 million in Q3 2025, and $57.3 million in Q2 2025.